Novavax Inc said on Monday its combined flu and Covid-19 vaccine produced functional antibodies against influenza and the coronavirus in a preclinical study.
The company said the NanoFlu/NVX-CoV2373 vaccine elicited robust responses to both influenza A and B and protected against the SARS-CoV-2 virus.
“Seasonal influenza and Covid-19 combination vaccines will likely be critical to combating emerging Covid-19 variants,” said Russell Wilson, the executive vice president and NanoFlu general manager of Novavax.
Hamsters that received the combined vaccine had heightened levels of Covid-19 antibodies two weeks after the first immunization, which increased significantly after a second dose, compared to animals that received the Covid-19 vaccine, NVX-CoV2373, alone, the company said.
Novavax said it expects to start clinical studies of the combined vaccine by the end of 2021.
Antibiotic use has surged globally, leading to a rise in antibiotic resistance, especially concerning in…
Choking is a leading cause of injury and death in young children, particularly those under…
Hard Water (Khara Pani) Leading To Hair Fall Hard water is rich in minerals and…
Discover how the rise in high blood pressure during pregnancy is impacting maternal and fetal…
"Discover the transformative power of six delicious homemade drinks that can help you naturally melt…
"Transform your weight loss routine with these eight delicious fat-flushing drinks that not only hydrate…